14 completed, 9 unknown, 3 terminated, 2 withdrawn. 13 Phase 2, 5 Phase 3, 5 Phase 4, 3 Phase 1.
Follow COMIRNATY: new trials by email Literature Review of COMIRNATY trials Research Report on COMIRNATY
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 56 | 2026-12-01 | 2026-09-17 |
| Phase 2 Study of GC4006A in Healthy Adults GC4006A, COMIRNATY - Covid-19 Prevention | Phase 2 | Enrolling by invitation | GC Biopharma Corp | 210 | 2026-10-26 | 2026-11-13 |
| Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose - COVID-19 | Phase 3 | Withdrawn | Murdoch Childrens Research Institute | 2024-04-01 | 2024-03-22 | |
| Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly Comirnaty - Vaccination; Infection, COVID-19 | Phase 2 | Terminated | Radboud University Medical Center | 48 | 2023-09-26 | 2024-03-28 |
| This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times. Comirnaty, Quadrivalent Influenza Vaccine - Influenza, Human, COVID-19 | Completed | Pfizer | 3442996 | 2023-05-05 | 2024-09-20 | |
| A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 RQ3013, Comirnaty - COVID-19 | Phase 1 | Unknown | Walvax Biotechnology Co., Ltd. | 120 | 2022-12-01 | 2022-11-18 |
| ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 ABNCoV2, Comirnaty - COVID-19 Disease | Phase 3 | Completed | Bavarian Nordic | 4205 | 2022-08-30 | 2025-02-24 |
| A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 RQ3013, Comirnaty - COVID-19 | Phase 1 | Unknown | Walvax Biotechnology Co., Ltd. | 120 | 2022-07-01 | 2022-05-31 |
| A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years SCTV01E, Comirnaty - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Unknown | Sinocelltech Ltd. | 400 | 2022-07-01 | 2022-04-14 |
| A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection | Phase 3 | Unknown | Sinocelltech Ltd. | 1800 | 2022-05-30 | 2023-04-10 |
| Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. Tozinameran - Standard Dose, Tozinameran - Fractional Dose - COVID-19 | Phase 3 | Completed | Murdoch Childrens Research Institute | 601 | 2022-05-27 | 2026-03-24 |
| Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose - COVID-19 | Phase 3 | Terminated | Murdoch Childrens Research Institute | 13 | 2022-05-02 | 2024-12-16 |
| A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine SCTV01C, Comirnaty - COVID-19, SARS-CoV2 Infection | Phase 2 | Withdrawn | Sinocelltech Ltd. | 2022-04-25 | 2024-02-09 | |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 400 | 2022-04-01 | 2022-04-11 |
| Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine - COVID-19, Corona Virus Infection | Phase 4 | Completed | University of Michigan | 137 | 2022-03-21 | 2026-03-27 |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine SCTV01E, Comirnaty - COVID-19, Sars-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 360 | 2022-03-20 | 2022-03-02 |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 600 | 2022-03-20 | 2022-03-02 |
| Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction Tozinameran - COVID-19, Vaccine Reaction | Phase 4 | Completed | Murdoch Childrens Research Institute | 51 | 2022-01-20 | 2023-02-09 |
| COVID Protection After Transplant-Immunosuppression Reduction Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen - Kidney Transplant Recipients, Liver Transplant Recipients | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2021-12-06 | 2026-04-23 |
| COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1 - Cancer | Phase 4 | Terminated | Jules Bordet Institute | 152 | 2021-12-01 | 2024-01-17 |
Showing 20 of 30. Sign in to see all of them.
COVID-19 (25) · Infections (2) · Influenza, Human (2) · Coronavirus Infections (1) · Hypersensitivity (1) · Neoplasms (1) · RNA Virus Infections (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Sinocelltech Ltd. (6) · Murdoch Childrens Research Institute (4) · Pfizer (3) · The University of Hong Kong (2) · Walvax Biotechnology Co., Ltd. (2) · Bavarian Nordic (1) · BioNTech SE (1) · Canadian Immunization Research Network (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fred Hutchinson Cancer Center (1) · GC Biopharma Corp (1) · Instituto de Investigación Hospital Universitario La Paz (1) · Jules Bordet Institute (1) · Medical University Innsbruck (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (5) · Australia (2) · Belgium (2) · Germany (2) · Hong Kong (2) · Japan (2) · Austria (1) · Canada (1) · Denmark (1) · Indonesia (1) · Italy (1) · Mongolia (1) · Netherlands (1) · South Korea (1) · Spain (1)
Benjamin J Cowling, PhD (2) · Lin Yuan (2) · Christian P. Larsen, MD, DPhil (1) · Cristobal Belda Iniesta, MD, PhD (1) · Dorothee von Laer, MD (1) · Dorry L. Segev, MD, PhD (1) · Eddy Fadlyana, Dr (1) · Hans de Graaf (1) · James Baker, MD (1) · Joanne Langley (1) · Jose R Arribas, MD, PhD (1) · Joshua Hill, MD (1)
PMID 34181880, PMID 35617826, PMID 35653438, PMID 35675370, PMID 35795713, PMID 36598621, PMID 37549680, PMID 37731938, PMID 38357398, PMID 39191745, PMID 39276621, PMID 39286494, PMID 39749328, PMID 41072276, PMID 41948336
2023 (1), U01AI138897 (1)